Curis (NASDAQ:CRIS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Curis (NASDAQ:CRIS) in a report issued on Friday morning, Benzinga reports. HC Wainwright currently has a $26.00 target price on the biotechnology company’s stock.

Curis Stock Performance

Shares of CRIS stock opened at $5.38 on Friday. Curis has a 52 week low of $3.80 and a 52 week high of $17.49. The stock has a market capitalization of $31.71 million, a PE ratio of -0.62 and a beta of 3.33. The stock’s fifty day moving average is $5.34 and its 200-day moving average is $9.13.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.36). The company had revenue of $2.55 million for the quarter, compared to analyst estimates of $2.20 million. Curis had a negative return on equity of 327.92% and a negative net margin of 468.18%. During the same quarter last year, the company earned ($2.40) EPS. As a group, analysts forecast that Curis will post -6.79 earnings per share for the current fiscal year.

Institutional Trading of Curis

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. lifted its holdings in Curis by 795.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after buying an additional 96,256 shares in the last quarter. CM Management LLC raised its position in shares of Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after acquiring an additional 95,000 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new position in shares of Curis during the first quarter valued at $219,000. Focused Wealth Management Inc lifted its stake in shares of Curis by 79.2% during the first quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 14,656 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after acquiring an additional 10,097 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.